Assignee
LDN PHARMA LTD
GB·6 granted patents·13 pending applications·4 citations·filing 2018–2024
Top patents by PatentIndex Score
19 records- 0182US11351165B2Agent that increases the expression of the opioid kappa 1 for the treatment of cancerLDN PHARMA LTD·Filed 2018·Granted Jun 7, 2022·2 cites·15 claims
- 0282US2025032481A1Priming of cancer cells with low dose naltrexoneLDN PHARMA LTD·Filed 2024·Application pending·0 cites
- 0377US11885796B2Assay to identify anti-cancer agentsLDN PHARMA LTD·Filed 2018·Granted Jan 30, 2024·1 cites·12 claims
- 0477US11304943B2Combination for use in the treatment of lung cancerLDN PHARMA LTD·Filed 2018·Granted Apr 19, 2022·1 cites·14 claims
- 0576US2023390388A1Treatment of Cancer with NaltrexoneLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 0673US2023349885A1Assay to identify anti-cancer agentsLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 0771US2023381171A1Autoimmune therapyLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 0870US2022040295A1Treatment of Cancer With NaltrexoneLDN PHARMA LTD·Filed 2021·Application pending·0 cites
- 0967US12029737B2Autoimmune therapyLDN PHARMA LTD·Filed 2019·Granted Jul 9, 2024·0 cites·5 claims
- 1056US2024108583A1Naltrexone compositionsLDN PHARMA LTD·Filed 2022·Application pending·0 cites
- 1156US2025281481A1Naltrexone for boosting the therapeutic utilty of 5-ht receptor agonistsLDN PHARMA LTD·Filed 2022·Application pending·0 cites
- 1256US2024285612A1Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3LDN PHARMA LTD·Filed 2022·Application pending·0 cites
- 1356US2024293395A1NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTSLDN PHARMA LTD·Filed 2022·Application pending·0 cites
- 1456US2024285613A1Treatment for autoimmune diseasesLDN PHARMA LTD·Filed 2022·Application pending·0 cites
- 1550US12324805B2Cancer treatmentLDN PHARMA LTD·Filed 2018·Granted Jun 10, 2025·0 cites·16 claims
- 1648US2022143010A1Cancer treatment comprising naltrexone and a cannabinoidLDN PHARMA LTD·Filed 2020·Application pending·0 cites
- 1746US12497663B2Method of monitoring treatmentLDN PHARMA LTD·Filed 2020·Granted Dec 16, 2025·0 cites·20 claims
- 1845US2022196659A1Method for determining efficacyLDN PHARMA LTD·Filed 2020·Application pending·0 cites
- 1944US2020101066A1Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancerLDN PHARMA LTD·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →